Peak Bio, Inc. (NASDAQ:PKBO – Get Rating)'s stock price rose 36.8% during mid-day trading on Friday . The company traded as high as $7.59 and last traded at $6.50. Approximately 529,309 shares traded hands during trading, an increase of 172% from the average daily volume of 194,357 shares. The stock had previously closed at $4.75.
Wall Street Analyst Weigh In
Separately, LADENBURG THALM/SH SH began coverage on Peak Bio in a research note on Friday, November 4th. They set a "buy" rating and a $15.00 price objective on the stock.
Peak Bio Stock Up 36.8 %
Peak Bio Company Profile
(Get Rating)
Peak Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients.
See Also
- Get a free copy of the StockNews.com research report on Peak Bio (PKBO)
- MarketBeat: Week in Review 11/21 – 11/25
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Peak Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peak Bio and related companies with MarketBeat.com's FREE daily email newsletter.